Journal
PEDIATRIC BLOOD & CANCER
Volume 63, Issue 4, Pages 701-705Publisher
WILEY-BLACKWELL
DOI: 10.1002/pbc.25866
Keywords
acute myeloid leukemia; allogeneic hematopoietic stem cell transplantation; children; relapse
Categories
Funding
- Japanese Ministry of Health, Labor, and Welfare
Ask authors/readers for more resources
BackgroundIn children with acute myeloid leukemia (AML), hematopoietic stem cell transplantation (HSCT) in first remission is indicated for patients with a relatively high risk of relapse. Second HSCT is a curative option; however, few reports have been published about a second HSCT in children for AML with posttransplantation relapse. ProcedureUsing the database provided by the Japanese Society of Hematopoietic Cell Transplantation, we analyzed 46 children with AML who underwent a second allogeneic HSCT after achieving a second remission. ResultsThe median duration from the first to second HSCT was 20 months, and the source of the second HSCT was related bone marrow (BM) in 22, related peripheral blood in 6, unrelated BM in 14, and unrelated cord blood in 4 patients. Twenty-five children eventually died of the following causes: progressive disease in 14 and transplant-related toxicities in 9. The 5-year overall survival rate was 41.7 7.7%. An interval of less than 24 months between the first and second HSCT was a significant poor prognostic factor. ConclusionsChildren with AML who experience a relapse after HSCT in first remission have a good chance of survival with a second HSCT if a second remission is achieved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available